To assess the need for biopsy using MRI and PETCT for prostatic disease
Not Applicable
- Conditions
- Health Condition 1: C61- Malignant neoplasm of prostate
- Registration Number
- CTRI/2023/07/055419
- Lead Sponsor
- Kasturba Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. PIRADS 3 LESIONS as defined by multiparametric MRI.
2. Time-interval between MRI and PET CT is 6 weeks.
3. Availability of histopathology report.
Exclusion Criteria
1. patients with prior radiotherapy, hormonal therapy, and transurethral resection of the prostate.
2. missed clinical data.
3. second primary malignancies.
4. prostatitis and prostatic abscess.
5. patients who refuse to give consent/are not willing to the procedure.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation between PIRADS scoring, PSMA PET CT & histopathological findings.Timepoint: After 1 year(31st July,2024)
- Secondary Outcome Measures
Name Time Method Compilation of data to assess the accuracy of imaging methods used & usefulness in avoiding unnecessary biopsiesTimepoint: 31st JULY, 2025